HomeMedical Oncology
Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
If a patient had a grade 2 infusion reaction to initial dose of IV Rituximab, can you give subcutaneous Rituximab for cycle 2 or continue with IV Rituximab?
1 Answers
Mednet Member
Medical Oncology · Riverside Methodist Hospitals/OhioHealth
I would likely continue IV rituximab until no more infusion reactions are observed before switching to SQ.
How do you prepare patients with DLBCL on the potential need for cellular therapies after progression on first line regimens?
3 Answers
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center
Once a patient is identified by the lymphoma team, they are referred to our cellular therapy service for full evaluation and discussion of CAR T cell risks, benefits, and logistics. The discussion of protocol versus commercial product, chemotherapy side effects versus CRS/ICANS, and severity includi...